AstraZeneca voluntarily pauses Ph III trials of AZD1222 for investigation

Sep 9, 2020

AstraZeneca announced it has voluntarily paused Ph III trials of AZD1222 to investigate a potentially unexplained illness in one of the trials. AZ said it will expedite the review of the single event to minimise any impact to the trial timeline.

Print Page Mail Article